WallStSmart

Aspire BioPharma, Inc. (ASBP)vsAlibaba Group Holding Ltd (BABA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 1070009112% more annual revenue ($1.04T vs $97,660). BABA leads profitability with a 7.0% profit margin vs 0.0%. BABA earns a higher WallStSmart Score of 55/100 (C-).

ASBP

Avoid

22

out of 100

Grade: F

Growth: 4.3Profit: 4.5Value: 5.0Quality: 5.3
Piotroski: 3/9Altman Z: -83.49

BABA

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 8.7Quality: 6.5
Piotroski: 2/9Altman Z: 2.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ASBP.

BABAUndervalued (+65.0%)

Margin of Safety

+65.0%

Fair Value

$435.28

Current Price

$100.96

$334.32 discount

UndervaluedFair: $435.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASBP1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

BABA4 strengths · Avg: 9.8/10
Market CapQuality
$249.37B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4610/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ASBP4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.80M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

BABA4 concerns · Avg: 2.8/10
Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
7.0%3/10

7.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-79.4%2/10

Earnings declined 79.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : ASBP

The strongest argument for ASBP centers on Price/Book.

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.46 suggests the stock is reasonably priced for its growth.

Bear Case : ASBP

The primary concerns for ASBP are Revenue Growth, EPS Growth, Market Cap.

Bear Case : BABA

The primary concerns for BABA are Return on Equity, Profit Margin, Piotroski F-Score.

Key Dynamics to Monitor

BABA carries more volatility with a beta of 0.46 — expect wider price swings.

BABA is growing revenue faster at 8.6% — sustainability is the question.

ASBP generates stronger free cash flow (-2M), providing more financial flexibility.

Monitor AUTO PARTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BABA scores higher overall (55/100 vs 22/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aspire BioPharma, Inc.

CONSUMER CYCLICAL · AUTO PARTS · USA

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.

Visit Website →

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

Want to dig deeper into these stocks?